Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login


Featured Clinical Trial of the Week: Erlotinib Plus Bevacizumab for NSCLC With EGFR Mutations

  • January 18 2013

    Share |
    Featured Clinical Trial of the Week: Erlotinib Plus Bevacizumab for NSCLC With EGFR Mutations

    Doctors and researchers don’t just look for individual drugs that can stop, slow or reverse the spread of lung cancer. They also search for combinations of treatments that work to compliment each other and improve patients’ lives.

    To help researchers fine-tune their understanding of which drug combinations work best, this clinical trial tests a combination of two drugs for patients whose tumors test positive for the EGFR mutation.

    Patients will be divided into two groups. Both groups will be given erlotinib (Tarceva®), a commonly prescribed treatment for non-small cell lung cancer that works by blocking a protein called the epidermal growth factor receptor (EGFR) from signaling cancer cells to grow. The second group will be given erlotinib plus bevacizumab (Avastin®), a monoclonal antibody that binds to a cell’s vascular endothelial growth factor (VEGF) protein, interrupting the development of new blood vessels that provide blood and nutrients to cancer tumors

    Researchers will examine the progress of patients in each group to determine whether the combination of erlotinib and bevacizumab drugs increases the time to disease progression vs. erlotinib alone.

    This trial is open to patients with stage IV non-small cell lung cancer and confirmed EGFR mutations who haven't yet had any other therapy. Visit for further eligibility and enrollment information for this clinical trial.
    If you’re looking for information on other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.


Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2018 Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.